Developing next generation anti-CD40 Ligand (CD40L) pathway antibodies
Eledon Pharmaceuticals, Inc. a patient focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease.
Our lead program, tegoprubart, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, transplant rejection, and neuroinflammation.
Our Strategy and Vision
Our strategy is to be focused, agile, driven, not cut corners, and guided by data and science. We are using this approach to develop and commercialize next generation anti-CD40 Ligand (CD40L) pathway antibodies for patients in need of potentially life-saving treatment options.
Tegoprubart Clinical Development
Eledon is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to conduct clinical and preclinical studies in kidney transplantation, xenotransplantation, IgA Nephropathy, and amyotrophic lateral sclerosis (ALS).
Would you like more information about Eledon or subscribe to receive news updates automatically?
News & Events
Stay current on recent company announcements, clinical updates, and our conference presentations